Advancing the health and well-being of animals and people


Principal Investigator: Bettina Wagner

Contact Information: Email: bw73@cornell.edu; Phone: 607-253-3813
Sponsor: University of Massachusetts, Amherst - USDA
Grant Number: 11-006340 A 00
Title: Development of High Priority Immune Reagents for Food Security
Annual Direct Cost: $61,699
Project Period: 09/01/10-08/31/13

DESCRIPTION (provided by applicant): WAGNER-HORSE COORDINATOR & CELL SURFACE PROTEIN EXPRESSION AND MONOCLONAL ANTIBODY PRODUCTION

The Wagner lab will test and characterize monoclonal antibodies generated against key equine cytokines and other regulatory proteins. The monoclonal antibodies will be developed in the Wagner lab (Cornell). Cytokines and chemokines for the horse will either be expressed at Cornell or in collaboration with scientists at Endogen. Dr. Wagner’s group will pursue the development of specific immunoassays for the targeted equine cytokines; ELISA, multiplex assays (horse and cattle) and intracellular staining for FACS analysis and multicolor flow cytometric analysis. These approaches allow for the characterization and quantification of each cytokine in biological fluids and culture supernatants (ELISA and multiplex assays), and cytokine production by individual cells (FACS analysis). These will include both equine-specific reagents as well as those generated for other species that may be cross-reactive with the equine cells. Dr. Wagner will make annual progress reports for horse reagents and meet regularly with the PI and other species PDs. Dr. Wagner will also express biological active recombinant proteins in mammalian cells. For the entire network she will use this experience and the established expression systems to express recombinant proteins for T cell receptors, immunoglobulins, CD molecules and other cell surface molecules of interest as defined by the individual species priority lists. All monoclonal antibodies for the horse and ten for swine as described/needed will be developed at the Cornell University. All remaining recombinant proteins will be sent to other collaborators on the grant to develop monoclonal antibodies.